Sandoz, a Novartis division, announced that the European Commission (EC) has approved Zessly (infliximab) for use in Europe. Zessly is approved for use in all indications of the reference medicine, Remicade, including rheumatoid arthritis, adult Crohn’s disease, pediatric Crohn’s disease, adult ulcerative colitis, pediatric ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. “The European Commission approval for…